Nature9d
The weight-loss drugs being tested in 2025: will they beat Ozempic?
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Novo Nordisk beats on Wegovy sales, expects slower 2025 growth
Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...
London Evening Standard9d
Wegovy obesity drug sales more than double but set to slow
It revealed that sales of Wegovy, a prescription weight loss injection, surged to 19.9 billion Danish kroner ... including ...
Novo Nordisk cashes in on obesity and diabetes drugs as profits swell
Novo Nordisk reported turnover from obesity treatments soared by 57 per cent to 65.1 billion Danish kroner last year, largely ...
Wegovy sales double to boost Novo Nordisk's fourth quarter as growth set to slow
LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than ...
Wegovy: sales of weight loss injection more than double
It revealed that sales of Wegovy, a prescription weight loss injection, surged to 19.9 billion Danish kroner (£2.2 billion) ...
Novo Nordisk shares rise on fourth-quarter profit beat, Wegovy sales jump
Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...
Will This New GLP-1 Drug be More Powerful Than Ozempic?
CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.
Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema Trial Results For Weight Loss
Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...
Investors Seek Answers on Novo Nordisk's Next-Gen Obesity Drug CagriSema
LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk is under pressure from investors for more information about its next-generation ...
Morningstar14d
Shareholders that lost money on Novo Nordisk A/S(NVO) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo's targeted expectation of at least 25% weight loss. The press release ...